drugset / Trial / NCT03431688
Tailored Therapy for Clarithromycin-Resistant H. Pylori
RandomizedParallel-groupSingle-blindTreatment
Summary
Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been few studies comparing treatment regimen in patient with clarithromycin-resistant H. pylori. We used sequencing-based clarithromycin resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline, metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin) regimen in patient with clarithromycin-resistant H. pylori.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2020-10-30
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amoxicillin | Other / unclassified | — | — |
| Comparator | Bismuth Potassium Citrate | Unknown | — | — |
| Comparator | tetracyclin | Unknown | — | — |
| Comparator | metonidazole | Unknown | — | — |